Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMARCB1 loss atypical teratoid rhabdoid tumor sensitive CFI-400945 Preclinical - Cell culture Actionable In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638). 28398638
SMARCB1 loss rhabdoid cancer sensitive EZH2 inhibitor Tazemetostat Preclinical - Cell line xenograft Actionable In a preclinical study, Tazemetostat (EPZ-6438) inhibited growth of SMARCB1-deficient malignant rhabdoid tumor cell lines in culture, and inhibited H3K27 trimethylation and induced tumor regression in a SMARCB1-deleted human malignant rhabdoid tumor cell line xenograft model (PMID: 23620515). 23620515
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04204941 Phase III Doxorubicin Doxorubicin + Tazemetostat Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Recruiting
NCT02114229 Phase II Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib Alisertib + Carboplatin + Cyclophosphamide + Vincristine Sulfate Cyclophosphamide + Topotecan Alisertib + Carboplatin + Cyclophosphamide + Etoposide Carboplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib + Cisplatin + Cyclophosphamide + Vincristine Sulfate Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT) Recruiting
NCT02601950 Phase II Tazemetostat A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting
NCT03274258 Phase II Ipilimumab + Nivolumab Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma Recruiting
NCT02601937 Phase I Tazemetostat A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Recruiting
NCT04416568 Phase II Ipilimumab + Nivolumab Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Recruiting